Brain Metastases from Thyroid Carcinoma: Prognostic Factors and Outcomes

Simple Summary In the following study, we aimed to analyze the characteristics, treatment modalities, and outcomes of patients with brain metastases (BMs) from thyroid cancer. To achieve this, from a total of 4320 thyroid cancer patients recorded in our institutional database over a 30-year period, data on 20 patients with brain metastases were retrospectively collected and analyzed. While thyroid cancer patients generally have a favorable prognosis, those with BMs often face a poorer outlook, marked by shorter survival times. Patients who experienced a longer interval (more than 24 months) between the diagnosis of thyroid cancer and the appearance of BMs had significantly better overall survival (OS). Surgical resection, combined with multidisciplinary adjuvant treatment, is essential for managing patients with BMs from thyroid cancer.Abstract Intracranial metastases from thyroid cancer are rare. Although the prognosis of thyroid cancer patients is generally favorable, the prognosis of patients with intracranial metastases from thyroid cancer has been considered unfavorable owing to lower survival rates among such patients compared to those without intracranial involvement. Many questions about their management remain unclear. The aim of the present study was to analyze the characteristics, treatment modalities, and outcomes of patients with brain metastases from thyroid cancer. Among 4320 patients with thyroid cancer recorded in our institutional database over a 30-year period, the data of 20 patients with brain metastasis were retrospectively collected and analyzed. The clinical characteristics, histological type of primary cancer and metastatic brain tumor, additional previous distant metastasis, treatment modalities, locations and characteristics on radiologic findings, time interval between the first diagnosis of primary thyroid cancer and brain metastasis, and survival were analyzed. Among our patient cohort, the mean age at initial diagnosis was 59.3 +/- 14.1 years, and at the manifestation of diagnosis of cerebral metastasis, the mean age was found to be 64.8 +/- 14.9 years. The histological types of primary thyroid cancer were identified as papillary in ten patients, follicular in seven, and poorly differentiated carcinoma in three. The average interval between the diagnosis of thyroid cancer and brain metastasis was 63.4 +/- 58.4 months (range: 0-180 months). Ten patients were identified as having a single intracranial lesion, and ten patients were found to have multiple lesions. Surgical resection was primarily performed in fifteen patients, and whole-brain radiotherapy, radiotherapy, or tyrosine kinase inhibitors were applied in the remaining five patients. The overall median survival time was 15 months after the diagnosis of BMs from TC (range: 1-252 months). Patients with thyroid cancer can develop brain metastasis even many years after the diagnosis of the primary tumor. The results of our study demonstrate increased overall survival in patients younger than 60 years of age at the time of diagnosis of brain metastasis. There was no difference in survival between patients with brain metastasis from papillary carcinoma and those with follicular thyroid carcinoma.